Toxicology Drug Screening Market Report 2026

The toxicology drug screening market size has grown strongly in recent years. It will grow from $21.44 billion in 2025 to $23.5 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to reliance on manual toxicology testing methods, limited laboratory automation, growing prevalence of substance abuse monitoring, increasing regulatory oversight, adoption of conventional bioanalytical instrumentation.

The toxicology drug screening market size is expected to see strong growth in the next few years. It will grow to $33.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to development of ai-driven predictive toxicology tools, integration of genomics and transcriptomics in screening, growth of contract research organizations (cros), rising demand for real-time drug monitoring systems, implementation of cloud-based and secure data management platforms. Major trends in the forecast period include growing adoption of high-throughput screening technologies, integration of lims and laboratory information systems, rising use of predictive and ai-powered toxicology platforms, expansion of workplace drug screening programs, enhanced focus on data security and compliance standards.

The rising prevalence of drug abuse is expected to drive the growth of the toxicology drug screening market in the coming years. Drug abuse refers to the harmful or excessive use of substances for non-medical purposes, leading to adverse effects on an individual’s health and overall quality of life. The increase in drug abuse is largely attributed to heightened stress levels and growing mental health challenges, which prompt some individuals to misuse substances as a coping mechanism. Toxicology drug screening plays a crucial role in addressing drug abuse by identifying the presence of drugs or their metabolites in the body, enabling early detection, diagnosis, and ongoing monitoring of substance misuse or overdose. For example, in August 2024, according to the National Records of Scotland (NRS), a Scotland-based government department, 1,172 drug misuse deaths were recorded in Scotland in 2023, representing a 12% increase, or 121 additional deaths, compared to 2022. Therefore, the rising prevalence of drug abuse is driving the growth of the toxicology drug screening market.

Major companies operating in the toxicology drug screening market are focusing on introducing innovative solutions, such as 3D liver microphysiological systems, which enable the cultivation of highly biomimetic human liver microtissues with organized cellular structures and active metabolic functions. A 3D liver microphysiological system (MPS) is an advanced in vitro platform designed to more accurately replicate the physiological environment of the human liver compared to traditional cell culture models and typically incorporates multiple human liver cell types. For instance, in February 2025, CN Bio Innovations Ltd., a UK-based life sciences company specializing in organ-on-a-chip technologies, launched the PhysioMimix DILI assay kit. This all-in-one laboratory kit is designed for in vitro profiling of human drug-induced liver injury and features a well-characterized 3D liver MPS that recreates metabolically active, highly functional human liver tissue along with Kupffer cells. The system also offers a plug-and-play format that simplifies adoption, reduces setup complexity, and shortens implementation timelines.

In September 2024, Scantox Group, a Denmark-based preclinical contract research organization providing toxicology testing services, acquired Gentronix for an undisclosed amount. Through this acquisition, Scantox Group aims to strengthen its early-stage toxicity testing capabilities by incorporating Gentronix’s expertise in genetic toxicology and predictive safety assessment, thereby enhancing its service portfolio for pharmaceutical and chemical companies. Gentronix is a UK-based preclinical contract research organization specializing in toxicology services, including drug screening.

Major companies operating in the toxicology drug screening market are Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, BD Bioscience, Quest Diagnostics, ICON plc, Agilent Technologies Inc., Eurofins Scientific SE, Wuxi AppTec, Charles River Laboratories International Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Evotec AG, Promega Corporation, The Jackson Laboratory, Clinical Reference Laboratory Inc., Enzo Life Sciences Inc., Covance Inc., Randox Toxicology, Alere Inc.

North America was the largest region in the toxicology drug screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the toxicology drug screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the toxicology drug screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the toxicology drug screening market by increasing the cost of importing laboratory equipment, reagents, and bioanalytical instruments. Segments such as high-throughput screening systems, genomics platforms, and cloud-based LIMS are most impacted, with regions like North America and Asia-Pacific experiencing higher production costs due to import duties. While tariffs create supply chain and pricing challenges, they also encourage local manufacturing, innovation in predictive toxicology solutions, and investment in domestic data management infrastructure.

The toxicology drug screening market research report is one of a series of new reports that provides toxicology drug screening market statistics, including toxicology drug screening industry global market size, regional shares, competitors with a toxicology drug screening market share, detailed toxicology drug screening market segments, market trends and opportunities, and any further data you may need to thrive in the toxicology drug screening industry. This toxicology drug screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

TToxicology drug screening is a testing process used to identify the presence of drugs, chemicals, or their metabolites in biological samples such as urine, blood, saliva, or hair. It is a medical testing method commonly employed to detect both legal and illegal substances in an individual’s body. The primary objective is to determine and quantify drug exposure, serving different purposes depending on the clinical, occupational, or regulatory context.

The main types of toxicology drug screening include monitoring and logging, security, storage and continuous integration or continuous deployment, management and orchestration, networking and data management services, and others. Monitoring and logging in toxicology drug screening involve the continuous tracking and recording of data generated during testing processes. The screening encompasses various test types such as acute systemic toxicity, dermal toxicity, carcinogenicity, ocular toxicity, genotoxicity, neurotoxicity, and organ-specific toxicity. It also utilizes technologies including high-throughput screening, genomics, transcriptomics, toxicogenomics, and molecular screening. Applications include immunotoxicity, systemic toxicity, developmental and reproductive toxicity (DART), endocrine disruption, and others, serving end users such as hospitals, clinics, contract research organizations (CROs), pharmaceutical companies, and workplace testing facilities.

The toxicology drug screening market consists of revenues earned by entities by providing services, such as pre-employment drug testing, sports drug testing, confirmatory testing, addiction treatment monitoring, and pain management monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.